verona pharma merck - Search News

News

Merck shells out $10 billion for Verona

Reuters on MSN · 4d

Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug Keytruda.

The Wall Street Journal on MSN · 3d

Merck to Buy Verona Pharma in $10 Billion Deal

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

MarketWatch on MSN · 4d

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s Ohtuvayre.

2d

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

1don MSN

Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

4don MSN

Merck spends $10 billion for Verona, gaining access to its COPD medication

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

BioPharma Dive2d

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

4don MSN

Merck buys Raleigh drugmaker for $10 billion, drawn by new COPD treatment

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results